{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:29:40Z","timestamp":1790126980669,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.esmoop.2026.106962","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T20:45:36Z","timestamp":1778186736000},"page":"106962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["First-in-human study of the dual A2A\/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-0540","authenticated-orcid":false,"given":"L.L.","family":"Siu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pudelko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ruth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8290-1114","authenticated-orcid":false,"given":"M.A.F.N.","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Zaynagetdinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3424-4882","authenticated-orcid":false,"given":"T.","family":"Kitzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.K.","family":"Guenhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Durutovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"McKean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.106962_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.csbj.2015.03.008","article-title":"A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy","volume":"13","author":"Leone","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106962_bib2","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41416-022-02013-z","article-title":"Impact of the selective A2(A)R and A2(B)R dual antagonist AB928\/etrumadenant on CAR T cell function","volume":"127","author":"Seifert","year":"2022","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106962_bib3","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106962_bib4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106962_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106962_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2026.106962_bib7","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3389\/fimmu.2019.00925","article-title":"Targeting adenosine in cancer immunotherapy to enhance T-cell function","volume":"10","author":"Vigano","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106962_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.14348\/molcells.2021.0044","article-title":"Clinical perspectives to overcome acquired resistance to anti\u2013programmed death-1 and anti\u2013programmed death ligand-1 therapy in non-small cell lung cancer","volume":"44","author":"Lee","year":"2021","journal-title":"Mol Cells"},{"key":"10.1016\/j.esmoop.2026.106962_bib9","article-title":"Acquired resistance to immune checkpoint blockades: the underlying mechanisms and potential strategies. Review","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106962_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4161\/onci.1.1.18068","article-title":"CD73 promotes tumor growth and metastasis","volume":"1","author":"Zhang","year":"2012","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106962_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13046-025-03416-5","article-title":"Research progress of CD73-adenosine signaling regulating hepatocellular carcinoma through tumor microenvironment","volume":"44","author":"Shan","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.esmoop.2026.106962_bib12","doi-asserted-by":"crossref","first-page":"13593","DOI":"10.18632\/oncotarget.24423","article-title":"Adenosine A(2A) receptor ligand recognition and signaling is blocked by A(2B) receptors","volume":"9","author":"Hinz","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2026.106962_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.coph.2020.08.003","article-title":"Targeting the A2AR in cancer; early lessons from the clinic","volume":"53","author":"Willingham","year":"2020","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106962_bib14","doi-asserted-by":"crossref","first-page":"748","DOI":"10.20517\/cdr.2023.63","article-title":"Unlocking antitumor immunity with adenosine receptor blockers","volume":"6","author":"Remley","year":"2023","journal-title":"Cancer Drug Resist"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106962_bib15","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1158\/1535-7163.MCT-23-0843","article-title":"Dual A2A\/A2B adenosine receptor antagonist M1069 counteracts immunosuppressive mechanisms of adenosine and reduces tumor growth in vivo","volume":"23","author":"Schiemann","year":"2024","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106962_bib16","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1158\/1078-0432.CCR-21-2742","article-title":"Phase I study of taminadenant (PBF509\/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab (PDR001), in patients with advanced non-small cell lung cancer","volume":"28","author":"Chiappori","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.esmoop.2026.106962_bib17","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1158\/1078-0432.CCR-22-0612","article-title":"Phase Ia\/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors","volume":"28","author":"Lim","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106962_bib18","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/jnci\/djad091","article-title":"Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression","volume":"115","author":"Evans","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"50","key":"10.1016\/j.esmoop.2026.106962_bib19","doi-asserted-by":"crossref","first-page":"39271","DOI":"10.1074\/jbc.M109.098293","article-title":"Adenosine A2A receptor is involved in cell surface expression of A2B receptor","volume":"285","author":"Moriyama","year":"2010","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106962_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0031-6997(24)01339-5","article-title":"Adenosine A2B receptors","volume":"49","author":"Feoktistov","year":"1997","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106962_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1124\/mol.113.088567","article-title":"Role of JunB in adenosine A2B receptor-mediated vascular endothelial growth factor production","volume":"85","author":"Ryzhov","year":"2014","journal-title":"Mol Pharmacol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106962_bib22","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/2326-6066.CIR-18-0056","article-title":"A2AR antagonism with CPI-444 induces antitumor responses and augments efficacy to anti-PD-(L)1 and anti-CTLA-4 in preclinical models","volume":"6","author":"Willingham","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"suppl 12","key":"10.1016\/j.esmoop.2026.106962_bib23","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/1538-7445.AM2022-3499","article-title":"Abstract 3499: M1069 as dual A2A\/A2B adenosine receptor antagonist counteracts immune-suppressive mechanisms of adenosine and reduces tumor growth in vivo","volume":"82","author":"Zaynagetdinov","year":"2022","journal-title":"Cancer Res"},{"issue":"suppl 12","key":"10.1016\/j.esmoop.2026.106962_bib24","article-title":"Abstract CT240: a first-in-human study of the dual A2A\/A2B adenosine receptor antagonist M1069 in patients with advanced solid tumors","volume":"82","author":"Siu","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2026.106962_bib25","first-page":"311","article-title":"Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis)","volume":"107","author":"Kaiser","year":"2009","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.esmoop.2026.106962_bib26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2147\/OPTH.S304272","article-title":"Comparison of visual acuity measurement using three methods: standard ETDRS chart, near chart and a smartphone-based eye chart application","volume":"15","author":"Tiraset","year":"2021","journal-title":"Clin Ophthalmol"},{"issue":"13","key":"10.1016\/j.esmoop.2026.106962_bib27","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/sim.3230","article-title":"Critical aspects of the Bayesian approach to phase I cancer trials","volume":"27","author":"Neuenschwander","year":"2008","journal-title":"Stat Med"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106962_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v089.i10","article-title":"Model-based dose escalation designs in R with crmPack","volume":"89","author":"Saban\u00e9s Bov\u00e9","year":"2019","journal-title":"J Stat Softw"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106962_bib29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/pst.326","article-title":"Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion","volume":"8","author":"Hummel","year":"2009","journal-title":"Pharm Stat"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106962_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","article-title":"Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer","volume":"10","author":"Fong","year":"2020","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106962_bib31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00262-024-03640-6","article-title":"A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer","volume":"73","author":"Falchook","year":"2024","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106962_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103446","article-title":"A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer","volume":"9","author":"Alonso-Gordoa","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.106962_bib33","article-title":"120MO Inupadenant combined with chemotherapy in patients with non-squamous NSCLC progressing on or after immune checkpoint inhibitor therapy: results from dose-finding part of the A2A-005 trial","volume":"24","author":"Cuppens","year":"2024","journal-title":"Immunooncol Technol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106962_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004089","article-title":"Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy","volume":"10","author":"Augustin","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.106962_bib35","article-title":"585 Phase 1 dose escalation trial of the selective A2B adenosine receptor antagonist PBF-1129 in patients with metastatic non-small cell lung cancer (mNSCLC)","volume":"10","author":"Owen","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.106962_bib36","article-title":"ADPORT-601: first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in patients with select advanced solid tumors","volume":"42","author":"Fong","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.106962_bib37","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1200\/JCO.2024.42.16_suppl.3508","article-title":"ARC-9: a randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC)","volume":"42","author":"Wainberg","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106962_bib38","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s10637-024-01462-y","article-title":"A randomized phase I study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants","volume":"42","author":"Gupta","year":"2024","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.esmoop.2026.106962_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz253.032","article-title":"Phase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies","volume":"30","author":"Powderly","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2026.106962_bib40","first-page":"283","article-title":"P655 EOS100850, an A2A receptor antagonist demonstrates efficacy in murine syngeneic tumor models regardless of adenosine concentrations. 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 2","volume":"7","author":"Romain Pirson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.esmoop.2026.106962_bib41","article-title":"176P Phase I study of INCB106385 alone or in combination with immunotherapy in advanced solid tumors","volume":"16","author":"Italiano","year":"2022","journal-title":"Immunooncol Technol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292600904X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292600904X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:12:34Z","timestamp":1780290754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292600904X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S205970292600904X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106962","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-human study of the dual A2A\/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106962"}}